Effect of LY3154207 on Cognition in Mild-to-Moderate Parkinson's Disease Dementia (PDD)

HS 2018-4423
Parkinsons, Movement disorders
Neal Hermanowicz, MD
UCI Main Campus in Irvine, Calif., and UC Irvine Medical Center in Orange, Calif.
To evaluate a new medication for the treatment of the cognitive symptoms of Parkinson’s disease dementia (PDD)

You can participate in this study if:

  •  You are a man or woman between 40 and 85 years of age and have Parkinson’s disease dementia.

You cannot take part in this study if:

  • You are a woman who could possibly become pregnant.
  • You have had a stroke or “mini-stroke” within the last six months.
  • You have high blood pressure that has caused other serious health problems.
  • You have a device implanted in your brain or you have had certain types of brain surgery.
  • You have, or have had, certain psychological problems.
  • You’ve had serious heart problems within the last six months.
  • You have certain types of liver disease.
  • You are participating in another clinical trial.
Participation will last approximately 17 to 18 weeks and include a total of 12 study visits and the use of several devices/technologies. 
There is no guarantee that subjects will receive any benefits from this study. Taking part in this study may or may not lead to improvement in symptoms related to Parkinson’s disease dementia. Findings from this study can potentially confirm the safety and efficacy of a treatment (orally administered LY3154207) for the neurocognitive symptoms of Parkinson’s disease dementia.
Between $25 and $150 per visit depending on the type of visit and the procedures involved. The maximum total compensation for completing all aspects of the clinical trial is $1575.
Drug therapy
Everlyne Gomez, UCI Department of Neurology Clinical Trials Unit